GD2CART for Osteosarcoma or Neuroblastoma
Contact
Description
This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory). This study involves an investigational cellular therapy called GD2CART. The study will be testing different doses of the study drug to find the safest dose.
Eligibility and criteria
IRB Number:
22-020029
Eligible age range:
Clinical trial phase:
Phase I
Official title:
What to expect
- Have an electrocardiogram (ECG) and echocardiogram (ECHO) before receiving the cellular therapy
- Undergo apheresis to remove white blood cells (called T Cells) from their blood
- Receive the cellular therapy called GD2CART via infusion. This is manufactured from participant's T Cells.
- Complete frequent clinic visits at CHOP
- Have research blood tests
- Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.